ATE460475T1 - Methode zur verhinderung der transplantatabstossung unter verwendung von tgf- beta zur induktion von t-suppressorzellen - Google Patents

Methode zur verhinderung der transplantatabstossung unter verwendung von tgf- beta zur induktion von t-suppressorzellen

Info

Publication number: ATE460475T1
Authority: AT; Austria
Prior art keywords: tgf; induce; beta; transplant rejection; suppressor cells
Prior art date: 2000-04-11

Application number

AT01926893T

Other languages

English (en)

Inventor

David Horwitz

Original Assignee

Univ Southern California

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-11

Filing date

2001-04-11

Publication date

2010-03-15

2001-04-11 Application filed by Univ Southern California filed Critical Univ Southern California

2010-03-15 Application granted granted Critical

2010-03-15 Publication of ATE460475T1 publication Critical patent/ATE460475T1/de

Links

206010052779 Transplant rejections Diseases 0.000 title abstract 2
238000000034 method Methods 0.000 title abstract 2
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1
239000000203 mixture Substances 0.000 abstract 1
210000000056 organ Anatomy 0.000 abstract 1
238000002054 transplantation Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/418—Antigens related to induction of tolerance to non-self
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4225—Growth factors
- A61K40/4229—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Transplantation (AREA)
Hematology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Mycology (AREA)
Cell Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)

AT01926893T 2000-04-11 2001-04-11 Methode zur verhinderung der transplantatabstossung unter verwendung von tgf- beta zur induktion von t-suppressorzellen ATE460475T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US19644600P	2000-04-11	2000-04-11
PCT/US2001/011898 WO2001077299A2 (en)	2000-04-11	2001-04-11	A METHOD TO PREVENT GRAFT REJECTION USING TGF-β TO INDUCE T SUPPRESSOR CELLS

Publications (1)

Publication Number	Publication Date
ATE460475T1 true ATE460475T1 (de)	2010-03-15

Family

ID=22725449

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01926893T ATE460475T1 (de)	2000-04-11	2001-04-11	Methode zur verhinderung der transplantatabstossung unter verwendung von tgf- beta zur induktion von t-suppressorzellen

Country Status (8)

Country	Link
US (3)	US6759035B2 (de)
EP (1)	EP1274833B1 (de)
JP (1)	JP5008810B2 (de)
AT (1)	ATE460475T1 (de)
AU (2)	AU2001253400B2 (de)
CA (1)	CA2405806A1 (de)
DE (1)	DE60141510D1 (de)
WO (1)	WO2001077299A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6358506B1 (en) *	1997-11-05	2002-03-19	University Of Southern California	Use of cytokines and mitogens to inhibit pathological immune responses
US20030157057A1 (en) *	1999-05-05	2003-08-21	Horwitz David A.	Methods for the induction of professional and cytokine-producing regulatory T cells
US6803036B1 (en)	1998-03-03	2004-10-12	University Of Southern California	Use of cytokines, cells and mitogens to inhibit graft versus host disease
US6447765B1 (en)	1998-03-03	2002-09-10	University Of Southern California	Use of cytokines and mitogens to inhibit graft versus host disease
JP5008810B2 (ja) *	2000-04-11	2012-08-22	ユニバーシティオブサザンカリフォルニア	抑制性Ｔ細胞を誘導するためにＴＧＦ−βを用いる移植拒絶反応を防止する方法
US7727523B2 (en) *	2001-08-13	2010-06-01	Yale University	Method for suppressing immune system response to transplanted tissue or cells
JP2005514054A (ja) *	2001-12-21	2005-05-19	ユニバーシティ・オブ・サザン・カリフォルニア	プロフェッショナルおよびサイトカイン産生制御ｔ細胞の誘導のための方法
US7172907B2 (en) *	2003-03-21	2007-02-06	Ge Healthcare Bio-Sciences Corp.	Cyanine dye labelling reagents with meso-substitution
WO2006050138A2 (en) *	2004-10-29	2006-05-11	Benaroya Research Institute At Virginia Mason	Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use
AU2006232374B2 (en) *	2005-04-01	2011-08-25	University Of Southern California	Preventing rejection of transplanted tissue using regulatory T cells
WO2006127152A2 (en) *	2005-04-05	2006-11-30	University Of Southern California	Methods for making and using regulatory t cells
PL2012814T3 (pl)	2006-04-12	2013-10-31	Genzyme Corp	Sposoby leczenia chorób autoimmunologicznych
EP2029729A2 (de) *	2006-05-31	2009-03-04	Genzyme Corporation	Verfahren zur verwendung von anti-thymocyt-globulin und verwandten wirkstoffen
WO2012032526A2 (en)	2010-09-08	2012-03-15	Yeda Research And Development Co. Ltd.	Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment
RU2506311C2 (ru) *	2008-10-30	2014-02-10	Йеда Рисёрч Энд Девелопмент Ко. Лтд.	Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний
AU2009314704A1 (en) *	2008-11-13	2010-05-20	Instituto De Medicina Molecular	Foxp3+ natural kiler T-cells and the treatment of immune related diseases
CN102971416B (zh)	2010-04-22	2018-03-30	南加州大学	用于扩增和稳定天然调节性t细胞的方法和组合物
US20110312886A1 (en) *	2010-06-16	2011-12-22	Allergan, Inc.	TGF-ß AND METHODS OF TREATING OCULAR AND OTHER DISEASES
AU2012305931B2 (en)	2011-09-08	2017-09-07	Yeda Research And Development Co. Ltd	Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
JP5907357B2 (ja)	2011-10-12	2016-04-26	Ｓｂｉファーマ株式会社	移植臓器生着促進剤
CN104245923B (zh)	2012-03-02	2018-04-20	加州大学评议会	同种异型抗原‑反应性调节t细胞的增殖
JP5904518B2 (ja)	2012-07-13	2016-04-13	Ｓｂｉファーマ株式会社	免疫寛容誘導剤
US20160046715A1 (en) *	2013-05-17	2016-02-18	Abwiz Bio, Inc.	T regulatory cells and uses thereof
AU2016291825B2 (en)	2015-07-16	2022-08-11	Yeda Research And Development Co. Ltd.	Genetically modified anti-third party central memory T cells and use of same in immunotherapy
CN108291203A (zh) *	2015-09-07	2018-07-17	国家健康科学研究所	Cd8+cd45rc低treg的新亚群及其用途
EP3571295B1 (de)	2017-01-18	2026-01-07	Yeda Research and Development Co. Ltd	Genetisch modifizierte vetozellen und verwendung davon in der immuntherapie
US10751368B2 (en)	2017-01-18	2020-08-25	Yeda Research And Development Co. Ltd.	Methods of transplantation and disease treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6406696B1 (en)	1989-10-27	2002-06-18	Tolerance Therapeutics, Inc.	Methods of stimulating the immune system with anti-CD3 antibodies
US6277635B1 (en)	1992-03-04	2001-08-21	Schering Corporation	Use of interleukin-10 to produce a population of suppressor cells
ZA931489B (en)	1992-03-04	1993-10-28	Schering Corp	Use of interleuken-10 to suppress graft-vs-host disease
US20020182730A1 (en) *	1995-07-26	2002-12-05	Micheal L. Gruenberg	Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
DK1028738T3 (da)	1997-11-05	2003-08-11	Univ Southern California	Anvendelse af cytokiner og mitogener til at inhibere patologiske immunresponser
US6358506B1 (en) *	1997-11-05	2002-03-19	University Of Southern California	Use of cytokines and mitogens to inhibit pathological immune responses
US20030157057A1 (en) *	1999-05-05	2003-08-21	Horwitz David A.	Methods for the induction of professional and cytokine-producing regulatory T cells
US6447765B1 (en)	1998-03-03	2002-09-10	University Of Southern California	Use of cytokines and mitogens to inhibit graft versus host disease
US6803036B1 (en) *	1998-03-03	2004-10-12	University Of Southern California	Use of cytokines, cells and mitogens to inhibit graft versus host disease
US6368636B1 (en) *	1998-03-18	2002-04-09	Osiris Therapeutics, Inc.	Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
ATE404662T1 (de)	1999-05-05	2008-08-15	Univ Southern California	Verwendung von zytokinen und mitogenen zur inhibierung von pathologischen immunantworten
WO2001016296A2 (en)	1999-09-01	2001-03-08	University Of Southern California	Use of cytokines, cells, and mitogens to inhibit graft versus host disease
US6685936B2 (en) *	1999-10-12	2004-02-03	Osiris Therapeutics, Inc.	Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
JP5008810B2 (ja) *	2000-04-11	2012-08-22	ユニバーシティオブサザンカリフォルニア	抑制性Ｔ細胞を誘導するためにＴＧＦ−βを用いる移植拒絶反応を防止する方法

2001
- 2001-04-11 JP JP2001575153A patent/JP5008810B2/ja not_active Expired - Fee Related
- 2001-04-11 WO PCT/US2001/011898 patent/WO2001077299A2/en not_active Ceased
- 2001-04-11 AU AU2001253400A patent/AU2001253400B2/en not_active Ceased
- 2001-04-11 CA CA002405806A patent/CA2405806A1/en not_active Abandoned
- 2001-04-11 AU AU5340001A patent/AU5340001A/xx active Pending
- 2001-04-11 EP EP01926893A patent/EP1274833B1/de not_active Expired - Lifetime
- 2001-04-11 AT AT01926893T patent/ATE460475T1/de not_active IP Right Cessation
- 2001-04-11 DE DE60141510T patent/DE60141510D1/de not_active Expired - Lifetime
- 2001-04-11 US US09/833,526 patent/US6759035B2/en not_active Expired - Lifetime
2004
- 2004-02-04 US US10/772,768 patent/US20040185034A1/en not_active Abandoned
2007
- 2007-10-30 US US11/929,254 patent/US20080318313A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20040185034A1 (en)	2004-09-23
JP2003530101A (ja)	2003-10-14
DE60141510D1 (de)	2010-04-22
US6759035B2 (en)	2004-07-06
AU2001253400B2 (en)	2007-03-01
AU5340001A (en)	2001-10-23
EP1274833B1 (de)	2010-03-10
WO2001077299A2 (en)	2001-10-18
WO2001077299A3 (en)	2002-03-28
US20080318313A1 (en)	2008-12-25
US20020006392A1 (en)	2002-01-17
JP5008810B2 (ja)	2012-08-22
EP1274833A2 (de)	2003-01-15
CA2405806A1 (en)	2001-10-18

Legal Events

Date	Code	Title	Description
2010-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE460475T1 (de)	2010-03-15	Methode zur verhinderung der transplantatabstossung unter verwendung von tgf- beta zur induktion von t-suppressorzellen
ATE458506T1 (de)	2010-03-15	Knochenmarkersatzmaterial-verbundwerkstoff, verfahren zu seiner herstelllung und kit
ATE430807T1 (de)	2009-05-15	Verfahren zur kultivierung von circovirus
WO2004044142A3 (en)	2004-10-21	Mesenchymal stem cells and methods of use thereof
DE69937888D1 (de)	2008-02-14	Verbesserung der herzfunktion durch transplantation mesenchymaler stammzellen
DE60123284D1 (de)	2006-11-02	Stabile feste enzymzusammensetzungen und verfahren zur ihrer verwendung
DE60125342D1 (de)	2007-02-01	Humane pankreatische epitheliale stammzellen, verfahren zur ihrer isolierung und verwendungen davon
DK0871414T3 (da)	2004-08-30	Fremgangsmåder til fremstilling af væv til implantering
ATE424147T1 (de)	2009-03-15	Biotechnisch erzeugte gefässprothese für die implantation
SE9303977D0 (sv)	1993-11-30	Verfahren zur herstellung von implantatkeramikmaterial, insbesonders von hydroxylapatit aufweisenden implantatkeramikmaterial
WO2003092471A3 (en)	2005-09-22	Cell-seeded extracellular matrix grafts
EP1082057A4 (de)	2005-06-08	Biologisch modellierte implantierbare prothesen
EA200800996A1 (ru)	2008-08-29	Способ получения т-клеточной популяции
DE50106328D1 (de)	2005-06-30	Verfahren zur herstellung bioaktiver implantatoberflächen
ATE263588T1 (de)	2004-04-15	Verfahren zur herstellung eines bioartifiziellen transplantates
IS5856A (is)	2001-02-23	Aðferðir þar sem integrín-mótlyf eru notuð til aðmeðhöndla margföld mergæxli og uppsog í bein af völdum mergæxla
ATE480615T1 (de)	2010-09-15	Verfahren zur proliferation von stammzellen
DE60128122D1 (de)	2007-06-06	Kernumprogrammierung bei iswi und ähnlichen chromatinremodellierenden atpasen
EP1767619A4 (de)	2008-07-23	Verfahren zur kultivierung embryonaler stammzellen unter verwendung eines aus der amniotischen membran stammenden faktors
NO20063772L (no)	2006-10-03	Sammensetninger og fremgangsmater vedrorende dyrking av neural stamceller med benmarg fra stromaceller
WO2000041713A3 (en)	2000-11-09	Composition and method for improving function of embryonic kidney transplants
WO2005017115A3 (en)	2005-06-02	Cord blood-derived hematopoietic progenitor cells
DE60136558D1 (de)	2008-12-24	Verfahren zur kultivierung humaner chondrozyten
ATE252918T1 (de)	2003-11-15	Hautmatrix zur abdeckung und regenerierung verletzter hautpartien sowie verfahren zu ihrer herstellung
MXPA03009312A (es)	2004-03-10	Metodo para trasplante autologo.